Vaccine adjuvants play an important role in improving immune responses, particularly in recombinant protein vaccines and other vaccine platforms that require stronger or more durable protection. Among the established adjuvant technologies, AS01 and Matrix-M have attracted considerable attention because of their ability to enhance immune activation through different mechanisms.
For vaccine developers looking for alternative adjuvant systems, domestic suppliers in China offer several options for research, formulation development, and potential commercial applications. However, selecting a suitable alternative involves more than comparing product names. Formulation composition, raw material quality, manufacturing capacity, technical documentation, and regulatory support all need to be evaluated.
This article reviews several domestic suppliers and compares key technologies to help vaccine manufacturers understand the available options.
1. Domestic Suppliers Offering AS01-Alternative Adjuvants
AS01 is a liposomal adjuvant system combining QS-21 and 3D-MPLA with a phospholipid-based carrier. Its formulation approach has become an important reference for developing alternative adjuvants.
Several Chinese companies have developed products based on similar technical concepts.
GC Biotech – GA101B Liposomal Adjuvant
GC Biotech offers GA101B, a two-component liposomal adjuvant developed with AS01B as its benchmark. Its formulation combines QS-21 and 3D-MPLA with a DOPC liposome carrier.
The company highlights its in-house production capabilities for key raw materials, including QS-21 and 3D-MPLA. This may help improve supply-chain control, cost management, and batch-to-batch consistency. Its stated manufacturing capacity includes 100 L cGMP-grade production, supported by DMF documentation and technical data packages for regulatory reference.
Huanuotai Bio – HA201 Adjuvant System
HA201 is another two-component liposomal adjuvant designed around an AS01-like formulation concept. Its base liposome scaffold contains DOPC at 1 mg/mL and cholesterol at 0.25 mg/mL, incorporating QS-21 and 3D-MLA.
The company identifies recombinant protein vaccines as one of its application areas. Its proprietary shingles vaccine has reportedly entered Phase III clinical trials, while the finished HA201 adjuvant is available for external supply. Huanuotai also reports completed FDA DMF filings for QS-21 and 3D-MLA.
For potential partners, clinical development progress and the availability of supporting documentation are important factors to review alongside formulation specifications.
Recbio – BFA01 Adjuvant System
Recbio has developed BFA01, a proprietary adjuvant system benchmarked against AS01. Its application in the company's recombinant shingles vaccine candidate, REC610, provides a clinical development reference.
Reported clinical findings include the induction of strong antigen-specific antibody and CD4+ T-cell responses. This makes BFA01 relevant to developers evaluating adjuvant technologies that require both humoral and cellular immune responses.
2. Matrix-M Alternative: GC Biotech's Nanoparticle Adjuvant
Matrix-M is a nanoparticle-based adjuvant technology, distinct from the liposomal structure used in AS01. For developers seeking a Matrix-M alternative, GC Biotech offers a two-component nanoparticle adjuvant, product code GC07002.
The formulation combines QS-7 at 85 μg/mL and QS-21 at 15 μg/mL, with a stated dose volume of 0.5 mL. Its nanostructure consists of two types of cage-like nanoparticles, each approximately 40 nm in size.
Several quality indicators are particularly relevant when assessing this type of product:
-
Saponin ratio: The QS-7/QS-21 ratio is controlled at 85:15.
-
Particle uniformity: The reported polydispersity index (PDI) is below 0.2.
-
Free saponin content: This is monitored because the amount of unbound saponin can influence product tolerability and hemolytic activity.
-
Quality documentation: GMP manufacturing conditions, certificates of analysis (COA), and analytical method validation reports are available according to the supplier.
Potential application areas include influenza vaccines, COVID-19 vaccines, recombinant protein vaccines, and other formulations where a strong Th1-oriented immune response is desired.
3. Two-Component vs. Three-Component Liposomal Adjuvants
Not all liposomal adjuvants use the same combination of immune-stimulating components. Understanding the formulation differences is important when selecting an appropriate platform.
A typical two-component system, such as the AS01B formulation concept, combines two immune agonists:
-
QS-21: A saponin-based immunostimulant associated with strong cellular immune responses.
-
3D-MPLA: A modified lipopolysaccharide-derived molecule that activates the TLR4 pathway.
-
Carrier: DOPC and cholesterol-based liposomes.
The combination is designed to stimulate innate immune pathways and support both antibody and cellular responses.
A three-component liposomal system introduces an additional immune-active component, QS-7, alongside QS-21 and 3D-MPLA. The formulation generally uses phospholipids and cholesterol as its carrier structure.
The purpose of adding QS-7 is to modify the overall immune-stimulation profile and potentially influence local reactogenicity. However, whether a three-component formulation offers better immunogenicity or tolerability depends on the specific formulation, antigen, dose, and experimental results.
Therefore, vaccine developers should avoid selecting a formulation based solely on the number of active components. Comparative immunogenicity, safety, stability, and antigen compatibility data are more meaningful selection criteria.
4. Synthetic or Natural-Source 3D-MPLA: Which Is More Suitable?
For AS01-like adjuvants, the source and manufacturing process of 3D-MPLA are important considerations.
Natural-source MPLA is generally obtained from bacterial lipopolysaccharide (LPS), followed by processing steps designed to remove or reduce the toxic activity associated with lipid A while retaining immunostimulatory properties. The resulting material can be used in formulations requiring TLR4 pathway activation.
Potential advantages of natural-source MPLA include an established manufacturing and research history, accumulated immunological data, and familiarity with its use in vaccine adjuvant development.
Synthetic MPLA, by contrast, offers the possibility of controlling molecular structure through chemical synthesis. However, manufacturing complexity, production costs, biological activity, and regulatory experience need to be assessed for each specific product.
The choice should be based on molecular characterization, impurity profiles, biological activity, manufacturing consistency, and available safety data rather than assuming that one source is universally superior. Claims of equivalence to an established adjuvant also require appropriate analytical and functional evidence.
5. Regulatory Documentation and Joint Filing Support
Regulatory preparation is often a major challenge when introducing a new adjuvant into vaccine development. Vaccine manufacturers may need to evaluate not only the finished formulation but also its active ingredients, raw materials, manufacturing controls, and analytical methods.
GC Biotech reports that it supports joint regulatory filings and provides technical documentation covering adjuvant raw materials, individual adjuvant molecules, and finished formulations in research or GMP grades.
Available documentation may include:
-
Certificates of Analysis (COA)
-
Product specifications and technical manuals
-
Standard Operating Procedures (SOPs)
-
Reference literature and technical data
-
Stability study reports
-
Analytical method validation documentation
The exact documentation package and its suitability for a specific regulatory pathway should be confirmed during project discussions. Additional stability studies, analytical support, and customized technical materials may also be arranged according to project requirements.
6. Formulation Guidance for Vaccine Developers
Selecting an adjuvant is only one part of vaccine formulation development. The antigen-to-adjuvant ratio, buffer composition, mixing sequence, and handling conditions can all affect the final formulation.
GC Biotech states that it can provide formulation guidance covering antigen-to-adjuvant mixing ratios, buffer requirements, and mixing workflows when customers purchase its adjuvant products.
These materials can help development teams establish an initial formulation process. Nevertheless, the final parameters should be verified through antigen-specific compatibility testing, stability studies, and appropriate preclinical evaluation rather than applied universally across different vaccine candidates.
7. Understanding Adjuvant Costs in Human and Veterinary Vaccines
Adjuvant cost is another important consideration, particularly for vaccine developers planning large-scale production.
According to the supplier's indicative estimates, adjuvant costs may be approximately RMB 10 or less per dose for human vaccines and around RMB 1 or less per dose for veterinary vaccines.
These figures should be treated as preliminary references rather than fixed market prices. Actual costs depend on the adjuvant type, formulation, dose, order volume, quality requirements, and manufacturing scale. A detailed quotation should be requested based on the intended vaccine application.
Conclusion
The development of AS01 and Matrix-M alternative adjuvants provides vaccine manufacturers with additional options for evaluating liposomal and nanoparticle-based technologies. Domestic suppliers such as GC Biotech, Huanuotai Bio, and Recbio offer different formulation approaches and development capabilities.
When comparing suppliers, vaccine developers should look beyond formulation similarities. Raw material traceability, manufacturing consistency, particle characteristics, biological activity, clinical evidence, regulatory documentation, and formulation support all contribute to a more informed decision.
For companies developing recombinant protein, influenza, COVID-19, shingles, or other vaccines, early technical communication and systematic comparative evaluation can help identify an adjuvant platform that fits the antigen, development stage, and regulatory strategy.
https://en.jicangbio.com/frequently-asked-questions-answers-and-recommendations.html
Comments (0)